Correction to “Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights”

ACS Chemical Neuroscience 2026 Open access

Read full text
Authors: Nina Kastner, Núria Nadal‐Gratacós, Selina Hemmer, Leticia Alves da Silva, J. M. T. McKee, Tamara Hell, Giulia Cicalese, Marion Holy, Fatemeh Kooti, Kathrin Jäntsch, Ricarda Baron, Naomi Shacham
+8 more Bruna Cuccurazzu, Adam L. Halberstadt, John D. McCorvy, Thomas Stockner, Markus Robert Meyer, Raúl López‐Arnau, Matthias Grill, Harald H. Sitte
DOI: 10.1021/acschemneuro.6c00136
Cited by: 0

Abstract

RecommendationsCorrection 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested doses of SDA and SDMA (2.5, 10, and 25 mg/kg) with saline (Figure 5B and 5E, respectively), a significant increase in thigmotaxis, reflected by reduced time spent in the center of the arena, was observed only for SDA at 10 mg/kg.

Fields of Study & Subjects

Psychedelics and Drug Studies Neurotransmitter Receptor Influence on Behavior Alkaloids: synthesis and pharmacology

Publication details

Journal / source
ACS Chemical Neuroscience
Volume
17
Issue
6
Pages
1227–1228
Publication date
4 March 2026
Language
EN